The type 2 diabetes or T2D mellitus has turn into an epidemic throughout the globe in
recent years. Various forms of treatment modalities have been available for patients with T2D
with some major classes of approved drugs that include Sulfonylureas, Meglitinides, Biguanides,
Thiazolidinedione, Alpha-glucosidase inhibitors, GLP-1 analogs, DPP-4 Inhibitors, and SGLT2
inhibitors. This review focuses on the drug metabolizing enzymes (DME), gene polymorphisms,
and inter-individual variability in therapeutics including adverse reaction effects involving Phase-I DME and Phase-II in general. This review
also covers some key anti-diabetic drugs with respect to their pharcogenomics.